BIOCON, Author at Biocon

Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab

Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, receives GMP compliance certificate from MHRA, UK

Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil

Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets

Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer

Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)

Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide

Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart

Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries

Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore